Synthesis and antiproliferative activity of new coumarin-based benzopyranone derivatives against human tumor cell lines

Medicinal Chemistry

Volumn 7, Issue 2, 2011, Pages 112-120

  Musa, Musiliyu A ^a   Zhou, Ailing ^b   Sadik, Omowunmi A ^b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b BINGHAMTON UNIVERSITY   (United States)

Author keywords

Anticancer agents; Antiproliferative agents; Basic amino side chain; Breast cancer; Coumarin; Cytotoxicity activity; Lung cancer

Indexed keywords

2 (4 HYDROXYPHENYL) 1 METHYL 3H BENZO [F] CHROMEN 3 ONE; 2 [4 (2 MORPHOLINOETHOXY)PHENYL 1 METHYL 3H BENZO[F]CHROMEN 3 ONE; 2 [4 (2 PIPERIDIN 1 YL) ETHOXY] PHENYL 1 METHYL 3H BENZO [F] CHROMEN 3 ONE; 2 [4 [2 (DIETHYLAMINO)ETHOXY]PHENYL] 1 METHYL 3H BENZO[F]CHROMEN 3 ONE; 4 (1 METHYL 3 OXO 3H BENZO [F] CHROMEN 2 YL)PHENYLACETATE; 6 (2 DIETHYLAMINO)ETHOXY 3 [4 [2 (DIETHYLAMINO)ETHOXY]PHENYL] 4 METHYL 2H CHROMEN 2 ONE; 6 (2 MORPHOLIN 1 YL)ETHOXY 3 [4 [2 (MORPHOLIN 1 YL)ETHOXY]PHENYL] 4 METHYL 2H CHROMEN 2 ONE; 6 (2 PIPERIDIN 1 YL)ETHOXY 3 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL] 4 METHYL 2H CHROMEN 2 ONE; 6 ACETOXY 3 (4 ACETOXYPHENYL) 4 METHYL 2H CHROMEN 2 ONE; 6 HYDROXY 3 (4 HYDROXYPHENYL) 4 METHYL 2H CHROMEN 2 ONE; 7 HYDROXY 3 PHENYL 4 [4 (2 PIPERIDINOETHOXY)BENZYL] 2H CHROMEN 2 ONE; AFIMOXIFENE; BENZOPYRANONE DERIVATIVE; COUMARIN; DIETHYLSTILBESTROL; ESTRADIOL; PYRAN DERIVATIVE; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

EID: 79952323666     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340611794859280     Document Type: Article

References (41)

1. Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol., 1996, 10(2), 119-131. (Pubitemid 26042544)
2. Gruvberger, S.; Ringner, M.; Chen, Y.; Panavally, S.; Saal, L. H.; Borg, A.; Ferno, M.; Peterson, C.; Meltzer, P. S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res., 2001, 61(16), 5979-5984. (Pubitemid 32762524)
3. Boyle, P. Breast cancer control: signs of progress, but more work required. Breast, 2005, 14(6), 429-438. (Pubitemid 41683563)
4. Swamy, N.; James, D. A.; Mohr, S. C.; Hanson, R. N.; Ray, R. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. Bioorg. Med. Chem., 2002, 10(10), 3237-3243. (Pubitemid 34855397)
5. Lerner, L. J.; Jordan, V. C. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res., 1990, 50(14), 4177-4189.
6. Wenckens, M.; Jakobsen, P.; Vedso, P.; Huusfeldt, P. O.; Gissel, B.; Barfoed, M.; Lundin Brockdorff, B.; Lykkesfeldt, A. E.; Begtrup, M. N-Alkoxypyrazoles as biomimetics for the alkoxyphenyl group in tamoxifen. Bioorg. Med. Chem., 2003, 11(8), 1883-1899. (Pubitemid 36349169)
7. Muchmore, D. B. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist, 2000, 5(5), 388-392.
8. Goldstein, S. R.; Siddhanti, S.; Ciaccia, A. V.; Plouffe, L., Jr. A pharmacological review of selective oestrogen receptor modulators. Hum. Reprod. Update, 2000, 6(3), 212-224. (Pubitemid 30348890)
9. Musa, M. A.; Khan, M. O.; Cooperwood, J. S. Synthesis and antiproliferative activity of coumarin-estrogen conjugates against breast cancer cell lines. Lett. Drug Des. Discov., 2009, 6(2), 133-138.
10. Nofal, Z. M.; El-Zahar, M. I.; AbdEl-Karim, S. S. Novel coumarin derivatives with expected biological activity. Molecules, 2000, 5, 99-113. (Pubitemid 38999065)
11. Takeuchi, Y.; Xie, L.; Cosentino, L. M.; Lee, K. H. Anti-AIDS Agents-XXVIII. Synthesis and Anti-HIV Activity of Methoxy Substituted 3', 4'-di-O-(-)Camphanoyl-(+)-Cis Khellactone (DCK) Analogues. Bioorg. Med. Chem. Lett., 1997, 7, 2573-2578. (Pubitemid 27455619)
12. 1 pyridyl coumarins. J. Med. Chem., 1964, 7, 446-449.
13. Al-Haiza, M. A.; Mostafa, M. S.; El-Kady, M. Y. Synthesis and Biological Evaluation of some new coumarin derivatives. Molecules, 2003, 8, 275-286. (Pubitemid 38982533)
14. Musiciki, B.; Periers, A. M.; Laurin, P.; Ferroud, D.; Benedetti, Y.; Lachaud, S.; Chatreaux, F.; Haesslein, J. L.; Lltis, A.; Pierre, C.; Khider, J.; Tessol, N.; Airault, M.; Demassey, J.; Dupuis-Hamelin, C.; Lassaigne, P.; Bonnefoy, A.; Vicat, P.; Klich, M. Improved antibacterial activities of coumarin antibiotics bearing 5',5'- dialkylnoviose: biological activity of RU 79115. Bioorg. Med. Chem. Lett., 2000, 10, 1695-1699. (Pubitemid 30495242)
15. Fylaktakidou, K. C.; Hadipavlou-Litina, D. J.; Litinas, K. E.; Nicolaides, D. N. Natural and Synthetic coumarin derivatives with Antiinflammatory/antioxidant activities. Curr. Pharm. Des., 2004, 10, 3813-3833. (Pubitemid 39409872)
16. Jung, J.; Kin, J.; Park, O. Simple and cost effective syntheses of 4-hydroxycoumarin. Synth. Commun., 1999, 29, 3587-3595. (Pubitemid 29384301)
17. Wang, Z. S.; Hara, K.; Dan-oh, Y.; Kasada, C.; Shinpo, A.; Suga, S.; Arakawa, H.; Sugihara, H. Photophysical and (photo) electrochemical properties of a coumarin dye. J. Phys. Chem. B, 2005, 109, 3907-3914. (Pubitemid 40402269)
18. Stanchev, S.; Momekov, G.; Jensen, F.; Manolov, I. Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. Eur. J. Med. Chem., 2008, 43(4), 694-706. (Pubitemid 351447326)
19. Thornes, R. D.; Daly, L.; Lynch, G.; Breslin, B.; Browne, H.; Browne, H. Y.; Corrigan, T.; Daly, P.; Edwards, G.; Gaffney, E.; Henley, J.; Healy, F.; Keane, F.; Lennon, F.; McMurray, N.; O'Loughlin, S.; Shine, M.; Tanner, A. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J. Cancer Res. Clin. Oncol., 1994, 120 (Suppl), S32-34. (Pubitemid 24142552)
20. Marshall, M. E.; Butler, K.; Fried, A. Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies. Mol. Biother., 1991, 3(3), 170-178.
21. Mohler, J. L.; Gomella, L. G.; Crawford, E. D.; Glode, L. M.; Zippe, C. D.; Fair, W. R.; Marshall, M. E. Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate, 1992, 20(2), 123-131.
22. McKie, J. A.; Bhagwat, S. S.; Brady, H.; Doubleday, M.; Gayo, L.; Hickman, M.; Jalluri, R. K.; Khammungkhune, S.; Kois, A.; Mortensen, D.; Richard, N.; Sapienza, J.; Shevlin, G.; Stein, B.; Sutherland, M. Lead identification of a potent benzopyranone selective estrogen receptor modulator. Bioorg. Med. Chem. Lett., 2004, 14(13), 3407-3410. (Pubitemid 38737136)
23. Brady, H.; Desai, S.; Gayo-Fung, L. M.; Khammungkhune, S.; McKie, J. A.; O'Leary, E.; Pascasio, L.; Sutherland, M. K.; Anderson, D. W.; Bhagwat, S. S.; Stein, B. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res., 2002, 62(5), 1439-1442. (Pubitemid 34407804)
24. Brady, H.; Doubleday, M.; Gayo-Fung, L. M.; Hickman, M.; Khammungkhune, S.; Kois, A.; Lipps, S.; Pierce, S.; Richard, N.; Shevlin, G.; Sutherland, M. K.; Anderson, D. W.; Bhagwat, S. S.; Stein, B. Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator. Mol. Pharmacol., 2002, 61(3), 562-568. (Pubitemid 34173034)
25. Kung Sutherland, M. S.; Lipps, S. G.; Patnaik, N.; Gayo-Fung, L. M.; Khammungkune, S.; Xie, W.; Brady, H. A.; Barbosa, M. S.; Anderson, D. W.; Stein, B. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GMCSF. Cytokine, 2003, 23(1-2), 1-14. (Pubitemid 36937195)
26. Kung Sutherland, M. S.; Brady, H.; Gayo-Fung, L. M.; Leisten, J.; Lipps, S. G.; McKie, J. A.; O'Leary, E.; Patnaik, N.; Anderson, D.W.; Bhagwat, S. S.; Stein, B. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat. Calcif. Tissue Int., 2003, 72(6), 710-716 (Pubitemid 36917326)
27. Andreescu, S.; Sadik, O. A.; McGee, D. W.; Suye, S. Autonomous multielectrode system for monitoring the interactions of isoflavonoids with lung cancer cells. Anal. Chem., 2004, 76(8), 2321-2330. (Pubitemid 38496075)
28. Andreescu, S.; Sadik, O. A.; McGee, D. W. Effect of natural and synthetic estrogens on a549 lung cancer cells: correlation of chemical structures with cytotoxic effects. Chem. Res. Toxicol., 2005, 18(3), 466-474. (Pubitemid 40393168)
29. Li, X.; Jain, N.; Russell, R. K.; Ma, R.; Branum, S.; Xu, J.; Sui, Z. Development of a Scalable Synthetic Process for Selective Bromination of 4-Methyl-3,7-Substituted Coumarins. Org. Process Res. Dev., 2006, 10, 354-360. (Pubitemid 43508451)
30. Kim, Y. W.; Mobley, J. A.; Brueggemeier, R. W. Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4- ones containing a basic side chain. Bioorg. Med. Chem. Lett., 2003, 13(8),1475-1478. (Pubitemid 36369192)
31. Sharma, A. P.; Saeed, A.; Durani, S.; Kapil, R. S. Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem., 1990, 33(12), 3216-3222.
32. Jain, N.; Xu, J.; Kanojia, R. M.; Du, F.; Jian-Zhong, G.; Pacia, E.; Lai, M. T.; Musto, A.; Allan, G.; Reuman, M.; Li, X.; Hahn, D.; Cousineau, M.; Peng, S.; Ritchie, D.; Russell, R.; Lundeen, S.; Sui, Z. Identification and structure-activity relationships of chromenederived selective estrogen receptor modulators for treatment of postmenopausal symptoms. J. Med. Chem., 2009, 52(23), 7544-7569.
33. Kim, Y. W.; Mobley, J. A.; Brueggemeier, R. W. Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4- ones containing a basic side chain. Bioorg. Med. Chem. Lett., 2003, 13(8), 1475-1478. (Pubitemid 36369192)
34. Amari, G.; Armani, E.; Ghirardi, S.; Delcanale, M.; Civelli, M.; Caruso, P. L.; Galbiati, E.; Lipreri, M.; Rivara, S.; Lodola, A.; Mor, M. Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity. Bioorg. Med. Chem., 2004, 12(14), 3763-3782. (Pubitemid 38801494)
35. Jones, C. D.; Blaszczak, L. C.; Goettel, M. E.; Suarez, T.; Crowell, T. A.; Mabry, T. E.; Ruenitz, P. C.; Srivatsan, V. Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2- (1-pyrrolidinyl)ethoxy]-phenyl]methanone. J. Med. Chem., 1992, 35(5), 931-938.
36. Wallace, O. B.; Bryant, H. U.; Shetler, P. K.; Adrian, M. D.; Geiser, A. G. Benzothiophene and naphthalene derived constrained SERMs. Bioorg. Med. Chem. Lett., 2004, 14(20), 5103-5106. (Pubitemid 39233375)
37. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J., 1999, 18(17), 4608-4618. (Pubitemid 29415516)
38. Croxtall, J. D.; Emmas, C.; White, J. O.; Choudhary, Q.; Flower, R. J. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol., 1994, 47(2), 197-202. (Pubitemid 24050873)
39. Caltagirone, S.; Ranelletti, F. O.; Rinelli, A.; Maggiano, N.; Colasante, A.; Musiani, P.; Aiello, F. B.; Piantelli, M. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol., 1997, 17(1), 51-59. (Pubitemid 127500820)
40. Coletta, A. A.; Benson, J. R.; Baum, M. Alternative mechanisms of action of antioestrogens. Breast Cancer Res. Treat., 1994, 31, 5-9.
41. Robertson, D. W.; Katzenellenbogen, J. A.; Hayes, J. R.; Katzenellenbogen, B. S. Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino) ethoxy]phenyl]-1-butene(tamoxifen, Nolvadex) having altered basicity. J. Med. Chem., 1982, 25(2), 167-171. (Pubitemid 12106638)